Answers are grounded in this paper and cite their sources.
Preclinical study reveals filaggrin wild-type predicts poor prognosis and immunotherapy response in bladder urothelial carcinoma, highlighting its value as a predictive biomarker.
Background: Bladder urothelial carcinoma (BLCA) is one of the most common urinary tract malignant tumors. Immune checkpoint blockade (ICB) therapy has significantly progressed the treatment of BLCA. This study aimed to investigate the role of specific genetic mutations that may serve as immune biomarkers for ICB therapy in BLCA. Methods: ) knockdown in BLCA 5637 and T24 cell lines. Results: could suppress BLCA cell proliferation and promote apoptosis. Conclusions: wild-type is associated with poor prognosis and can be used to predict ICB response for BLCA treatment. This research provides a new basis and ideas for guiding the clinical application of BLCA immunotherapy.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: